

10th of May 2022

Dear Healthcare Professional,

Change to tablet appearance- Motetis

Douglas Pharmaceuticals Ltd wishes to inform you of changes to the markings of Motetis 25 mg (tetrabenazine) tablets.

The new tablet presentation has "TE 25" embossed on one face with a scoreline on the other. This presentation is now available in the market. Previously, the tablet had a scoreline on one face with the other face plain.

The new tablet appearance is shown below. Please note, this is not shown to actual size.

New tablet appearance



Please ensure that all of your relevant staff are made aware of the contents of this letter and that the information is communicated to your patients.

Should you have any questions regarding the new presentation or formulation, please contact us on +64 9 835 0660 or alternatively through our contact form via our website at www.douglas.co.nz

Reporting Adverse Events

Reporting suspected adverse reactions has an important role in monitoring the benefit/risk balance of medicines. Please report any suspected adverse events via email to Douglas Pharmaceuticals Ltd at drugsafety@douglas.co.nz. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) at <https://nzphvc.otago.ac.nz/>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.

Kind regards

Roger Smart

Regulatory and Clinical Affairs Strategic Business Partner



+64 9 835 0660



Douglas Pharmaceuticals Ltd
Central Park Drive, Lincoln
PO Box 45 027, Auckland 0651



www.douglas.co.nz